Dr Martin Hutchings (Copenhagen University Hospital, Denmark) presented the findings of the dose-escalation phase 1-2 GEN3013 trial in B-cell non-Hodgkin lymphoma (B-NHL) in an e-poster . Epcoritamab administered subcutaneously demonstrated a favourable safety profile, with initial data suggesting promising and durable responses.
The rationale behind this study stems from the fact that most B-NHL patients relapse or become refractory (R/R) to CD20-specific monoclonal antibodies, but CD3xCD20 bispecific antibodies have shown promising results and may ameliorate resistance. The current poster presented dose-escalation data from the ongoing trial testing epcoritamab, a novel, subcutaneously administered CD3xCD20 agent. The primary endpoints were to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). A key secondary objective was to analyse initial anti-tumour efficacy...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma Next Article
Two trials: acalabrutinib in CLL »
Table of Contents: EHA 2020
Plasma Cell Dyscrasias
Bench-to-Bedside Science from the Presidential Symposium
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.